Emerging in the landscape of obesity therapy, retatrutide presents a different method. Unlike many available medications, retatrutide functions as a double agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. The concurrent activation fosters multiple advantageous effects,